Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

The 'Dual-Pathway' Strategy After Acute Coronary Syndrome: Rivaroxaban and Anti-platelet Agents in the ATLAS ACS 2-TIMI 51 Trial.

Cohen M, Iyer D.

Cardiovasc Ther. 2014 Jun 4. doi: 10.1111/1755-5922.12083. [Epub ahead of print]

PMID:
24894120
[PubMed - as supplied by publisher]
2.

Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.

Vardi M, Debidda M, Bhatt DL, Mauri L, Cannon CP.

Clin Cardiol. 2014 Feb;37(2):103-7.

PMID:
24672813
[PubMed - in process]
3.

The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.

Reddy P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Mar 21. [Epub ahead of print]

PMID:
24659084
[PubMed - as supplied by publisher]
4.

Peri-operative management of anticoagulation and antiplatelet therapy in gastrointestinal surgery.

Degirmenci SE, Steib A.

J Visc Surg. 2014 Apr;151(2):125-35. doi: 10.1016/j.jviscsurg.2014.01.009. Epub 2014 Mar 14.

PMID:
24631468
[PubMed - in process]
Free Article
5.

Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.

Ice DS, Shapiro TA, Gnall EM, Kowey PR.

Am J Cardiol. 2014 Mar 1;113(5):888-96. doi: 10.1016/j.amjcard.2013.11.046. Epub 2013 Dec 12. Review.

PMID:
24528617
[PubMed - indexed for MEDLINE]
6.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3.

PMID:
24383983
[PubMed - in process]
7.

Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.

Ganetsky VS, Hadley DE, Thomas TF.

Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13.

PMID:
24338703
[PubMed - in process]
8.

Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.

Lee MS, Wolfe M, Stone GW.

JACC Cardiovasc Interv. 2013 Nov;6(11):1149-52. doi: 10.1016/j.jcin.2013.08.003. Review.

PMID:
24262614
[PubMed - indexed for MEDLINE]
9.

The clinical and economic impact of bivalirudin for percutaneous coronary intervention.

Malik N, Gershlick AH.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):699-706. doi: 10.1586/14737167.2013.844650. Review.

PMID:
24219045
[PubMed - indexed for MEDLINE]
10.

Novel antiplatelet and anticoagulant agents in the cardiac care unit.

Garg VP, Halperin JL.

Cardiol Clin. 2013 Nov;31(4):533-44, viii. doi: 10.1016/j.ccl.2013.07.001. Epub 2013 Aug 9. Review.

PMID:
24188219
[PubMed - indexed for MEDLINE]
11.

A new paradigm shift in antithrombotic therapy.

Pudusseri A, Shameem R, Spyropoulos AC.

Front Pharmacol. 2013 Oct 21;4:133. doi: 10.3389/fphar.2013.00133. Review.

PMID:
24155721
[PubMed]
Free PMC Article
12.

Antiplatelet and anticoagulation medications and the surgical patient.

Yorkgitis BK, Ruggia-Check C, Dujon JE.

Am J Surg. 2014 Jan;207(1):95-101. doi: 10.1016/j.amjsurg.2013.04.004. Epub 2013 Oct 15. Review.

PMID:
24139554
[PubMed - indexed for MEDLINE]
13.

Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.

Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR; Canadian Cardiovascular Society.

Can J Cardiol. 2013 Nov;29(11):1334-45. doi: 10.1016/j.cjca.2013.07.001. Epub 2013 Aug 23. Review.

PMID:
23978596
[PubMed - indexed for MEDLINE]
14.

Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.

Doraiswamy VA, Slepian MJ, Gesheff MG, Tantry US, Gurbel PA.

Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1259-67. doi: 10.1586/14779072.2013.827469. Epub 2013 Aug 22. Review.

PMID:
23968500
[PubMed - indexed for MEDLINE]
15.

New developments in parenteral anticoagulation for arterial and venous thromboembolism.

van Es N, Bleker SM, Büller HR, Coppens M.

Best Pract Res Clin Haematol. 2013 Jun;26(2):203-13. doi: 10.1016/j.beha.2013.07.010. Epub 2013 Jul 21. Review.

PMID:
23953908
[PubMed - indexed for MEDLINE]
16.

New oral anticoagulants after acute coronary syndrome.

Bennaghmouch N, Ten Berg JM.

Best Pract Res Clin Haematol. 2013 Jun;26(2):141-50. doi: 10.1016/j.beha.2013.07.006. Epub 2013 Jul 22. Review.

PMID:
23953902
[PubMed - indexed for MEDLINE]
17.

Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting.

Reed GW, Cannon CP.

Clin Cardiol. 2013 Oct;36(10):585-94. doi: 10.1002/clc.22167. Epub 2013 Jul 19. Review.

PMID:
23873635
[PubMed - indexed for MEDLINE]
18.

ACP Journal Club. Review: New oral anticoagulants added to antiplatelets reduce CV events but increase bleeding after ACS.

Vaishnava P, Eagle KA.

Ann Intern Med. 2013 Jul 16;159(2):JC7. doi: 10.7326/0003-4819-159-2-201307160-02007. No abstract available.

PMID:
23856705
[PubMed - indexed for MEDLINE]
19.

Review of newer anticoagulants and anti-platelet agents in acute coronary syndrome and cardiovascular diseases.

Gosavi S, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):194-202.

PMID:
23855519
[PubMed - in process]
20.

Emerging antithrombotic drugs for acute coronary syndrome.

Shimada YJ, Giugliano RP.

Expert Opin Emerg Drugs. 2013 Sep;18(3):307-18. doi: 10.1517/14728214.2013.819342. Epub 2013 Jul 13. Review.

PMID:
23848430
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk